Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Aerie Pharmaceuticals

Here Are 10 Biotech Stocks That Would Have Netted You $12,000 This Year

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2022

Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million

Alcon will buy glaucoma drugs maker Aerie Pharmaceuticals in a $770 million deal that sent the biotech stock flying Tuesday.

Investors Business Daily

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Aerie Pharmaceuticals Begins Patient Dosing In Late-Stage Dry Eye Disease Study

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has dosed the first patient in the Phase 3 COMET-2 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED).

inkl

Read news from The Economist, FT, and more,
with one subscription

HC Wainwright & Co. Maintains Buy Rating for Aerie Pharmaceuticals: Here's What You Need To Know

HC Wainwright & Co. Maintains Buy Rating for Aerie Pharmaceuticals: Here's What You Need To Know

HC Wainwright & Co. has decided to maintain its Buy rating of Aerie Pharmaceuticals (NASDAQ:AERI) and lower its price target from $25.00 to $20.00. Shares of Aerie Pharmaceuticals are trading down 3.54% over the last 24 hours, at $6.03 per share.

Earnings Preview For Aerie Pharmaceuticals

Earnings Preview For Aerie Pharmaceuticals

Aerie Pharmaceuticals (NASDAQ:AERI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Aerie Pharmaceuticals will report an earnings per share (EPS) of $-0.65.

Recap: Aerie Pharmaceuticals Q4 Earnings

Recap: Aerie Pharmaceuticals Q4 Earnings

Aerie Pharmaceuticals (NASDAQ:AERI) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

1

Organisations

Food and Drug Administration

Arista Networks

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Kidney Transplant

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

243,773 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play